Articles from Imvax, Inc.

Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced top line results from its randomized, multicenter, double-blind, placebo-controlled Phase 2b clinical trial of IGV-001 in 99 patients with newly diagnosed glioblastoma (ndGBM). Glioblastoma is a highly aggressive brain cancer with an average life expectancy of just 12 to 15 months, and a five-year survival rate of under six percent. It has been 20 years since the last improvement to the standard of care for the treatment of ndGBM.

Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced the closing of a $29 million financing round from existing investors. Over the past 21 months, the Company has raised $86 million to support the completion of its randomized, multicenter, double-blind, placebo-controlled Phase 2b trial of IGV-001 in patients with newly diagnosed glioblastoma (ndGBM). IGV-001 is derived from Imvax’s proprietary Goldspire® immuno-oncology platform, which is designed to use a patient’s own tumor cells to induce a broad and durable immune response against tumors. The primary endpoint of the Phase 2b trial is progression free survival (PFS).

Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole-tumor derived immunotherapies, today announced an oral presentation and two poster presentations at the 2024 Society for NeuroOncology (SNO) 29th Annual Meeting in Houston, Texas, from November 21-24, 2024. Separately, the Company will also host a symposium focused on the development of IGV-001 for the treatment of newly diagnosed glioblastoma.

Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced the completion of enrollment in its randomized, multicenter, double-blind, placebo-controlled Phase 2b clinical trial of IGV-001 in patients with newly diagnosed glioblastoma (ndGBM). IGV-001 is derived from Imvax’s proprietary Goldspire™ immuno-oncology platform, which is designed to use a patient’s own tumor cells to induce a broad and durable immune response against tumors. The primary endpoint of the Phase 2b trial is Progression Free Survival (PFS) and top-line data is expected by mid-2025.

Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced details of its two poster presentations at the 2023 Society for NeuroOncology (SNO) 28th Annual Meeting, which was held in Vancouver, British Columbia, Canada, from November 15-19, 2023.

Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced two poster presentations at the 2023 Society for NeuroOncology (SNO) 28th Annual Meeting in Vancouver, British Columbia, Canada, from November 15-19, 2023.

Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced the initial closing of a $23 million financing round led by the company’s significant existing investors. The proceeds from the initial closing will be used to support the company’s ongoing randomized, multicenter, double-blind, placebo-controlled Phase 2b clinical trial of IGV-001 in patients with newly diagnosed glioblastoma (GBM). The trial is enrolling as expected, and the company will continue additional fundraising over the next several months.

Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced the publication of preclinical research with IGV-001 in Journal for ImmunoTherapy of Cancer, the official journal of the Society for Immunotherapy of Cancer (SITC). The article — “A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma” — is available online.

Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced a poster presentation providing additional mechanistic insights into its Goldspire™ platform based on preclinical studies of its lead product candidate, IGV-001, for the treatment of glioblastoma (GBM). These data are being presented at the American Association for Cancer Research Annual Meeting in Orlando, FL, running from April 14-19, 2023.

Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced dosing of the first patient in the company’s randomized, multicenter, double-blind, placebo-controlled Phase 2b clinical trial of IGV-001 in patients with newly diagnosed glioblastoma (ndGBM).

Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, announced two poster presentations at the 2022 Society for Immunotherapy of Cancer (SITC) Meeting in Boston, MA, from November 10-12, 2022.

Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced two poster presentations at the 2022 Society for Immunotherapy of Cancer (SITC) Meeting in Boston, MA, from November 10-12, 2022.

Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, is presenting data today at the 2022 International Cancer Immunotherapy Conference (CICON) in New York City, NY.

Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, announced that Chief Executive Officer John P. Furey will be presenting at the following upcoming investor conferences:

Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, is presenting data on the activity of the company’s tumor-derived immunotherapies in glioblastoma and other solid tumors at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, La.

Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today presented data showing the mechanisms by which IGV-001 produces broad immune activation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. The data from in vitro and in vivo studies highlight the effects of IGV-001 on inducing both innate and adaptive immune responses to tumor cells and point to the potential mechanism behind observed clinical activity for IGV-001 in the treatment of glioblastoma.

Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced a poster presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington, D.C., from November 10-14, 2021.

Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, announced the appointment of John M. Limongelli as the Company’s Chief Legal Officer effective September 16, 2021.